Development of a colorimetric paper fluidic dipstick assay for measurement of glycated albumin to monitor gestational diabetes at the point-of-care

Gestational diabetes mellitus (GDM) affects between 2 and 14% of pregnant women in the United States every year. Currently, glucose hemoglobin A1c (HbA1c) are standard biomarkers used to monitor GDM but HbA1c is representative 2–3 months glycemic data too infrequent for managing clinical impact while provides multiple daily readings which arguably not entirely necessary mild moderate often result non-compliance from patient's side. Thus, there a need an intermediate biomarker can be effectively status patients. Serum albumin, most abundant protein blood, undergoes non-enzymatic glycation bloodstream. Owing its half-life ~21 days, it as biomarker. Normal level albumin 10 16% whereas diabetic patients much higher, 16 40%. point-of-care (POC) monitoring system detect glycated (GA) % total serum has been developed here. Specifically, dipstick paper fluidic test measure that aptamer assay with gold nanoparticles produce colorimetric measurements. Both unglycated versions were measured their relevant physiological concentration ranges – 50 μM–300 μM limit detection (LoD) 6.5 500 μM–750 LoD 21 albumin. The use aptamers recognition elements, instead commonly antibodies, only provided required sensitivity, specificity, dynamic range they also have added advantage being stable at room temperature extended period time providing potential these tests (POC).